Visual Performance of Prototype Contact Lens Designs

Sponsor
Brien Holden Vision (Industry)
Overall Status
Completed
CT.gov ID
NCT02193555
Collaborator
(none)
91
1
2
4
22.5

Study Details

Study Description

Brief Summary

The aim of this study is to assess the visual performance of prototype soft contact lens designs compared to a commercially available contact lens

Condition or Disease Intervention/Treatment Phase
  • Device: Etafilcon A, Senofilcon A
N/A

Detailed Description

Prospective, participant-masked, randomised, stratified, crossover, bilateral wear, dispensing clinical trial where participants will wear the prototype (test) and the commercial (control) lens. A minimum of an overnight washout period is required between the fitting /assessment visits.

Study Design

Study Type:
Interventional
Actual Enrollment :
91 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Official Title:
Visual Performance of Prototype Contact Lens Designs
Study Start Date :
Jul 1, 2014
Actual Primary Completion Date :
Sep 1, 2014
Actual Study Completion Date :
Nov 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Other: Non-presbyopic group

Non-presbyopic group: age ranging from 7 to 39 years At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue 1- Day Moist, etafilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit. For each fitting visit, lenses will be fitted bilaterally.

Device: Etafilcon A, Senofilcon A
1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
Other Names:
  • Control lenses
  • Non-presbyopic group
  • Brand name: 1-Day Acuvue® Moist®
  • Lens material: Etafilcon A
  • Presbyopic group
  • Brand name: Acuvue® Oasys® for Presbyopia
  • Lens material: Senofilcon A
  • Test lens
  • Brand name: Iteration X
  • Other: Presbyopic group

    Presbyopic group: age 40 and above At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue Oasys for Presbyopia, senofilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit. For each fitting visit, lenses will be fitted bilaterally.

    Device: Etafilcon A, Senofilcon A
    1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
    Other Names:
  • Control lenses
  • Non-presbyopic group
  • Brand name: 1-Day Acuvue® Moist®
  • Lens material: Etafilcon A
  • Presbyopic group
  • Brand name: Acuvue® Oasys® for Presbyopia
  • Lens material: Senofilcon A
  • Test lens
  • Brand name: Iteration X
  • Outcome Measures

    Primary Outcome Measures

    1. Visual performance [After about 20 minutes of lens wear]

      Visual acuity

    Secondary Outcome Measures

    1. Subjective responses [After about 40 minutes of lens wear]

      Subjective ratings of vision

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    7 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.

    • Be at least 7 years old, male or female.

    • Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.

    • Have ocular health findings considered to be "normal" and which would not prevent the participant from safely wearing contact lenses.

    • Correctable to at least 6/12 (20/40) or better with both eyes with contact lenses.

    • Be suitable and willing to wear contact lenses.

    Exclusion Criteria:
    • Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses.

    • Any systemic disease that adversely affects ocular health e.g. diabetes, Graves' disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.

    • Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.

    • Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.

    • Eye surgery within 12 weeks immediately prior to enrolment for this trial.

    NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Brien Holden Vision Institute, Clinical Research Trials Center Sydney New South Wales Australia 2052

    Sponsors and Collaborators

    • Brien Holden Vision

    Investigators

    • Principal Investigator: Jiyoon Chung, BOptom, Brien Holden Vision Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Brien Holden Vision
    ClinicalTrials.gov Identifier:
    NCT02193555
    Other Study ID Numbers:
    • CRTC2014-02
    First Posted:
    Jul 17, 2014
    Last Update Posted:
    Nov 6, 2014
    Last Verified:
    Jul 1, 2014
    Keywords provided by Brien Holden Vision
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 6, 2014